NCT01751165

Trial name or title	'Open‐label study to evaluate the safety and immunogenicity of GSK Biologicals' herpes zoster vaccine GSK1437173A in adults aged ≥ 50 years'
Methods	Allocation: randomised Endpoint classification: efficacy study Intervention model: parallel assignment Masking: open‐label Primary purpose: prevention
Participants	354 healthy volunteers, 50 years and older, both genders
Interventions	1. HZ/su‐0,2 Group. Participants will receive HZ/su vaccine on a 0.2 month schedule 2. HZ/su‐0,6 Group. Participants will receive HZ/su vaccine on a 0.6 month schedule 3. HZ/su‐0,12 Group. Participants will receive HZ/su vaccine on a 0.12 month schedule
Outcomes	Anti‐gE humoral immunogenicity in terms of antibody concentration, occurrence of solicited local and general symptoms, occurrence of unsolicited symptoms, occurrence of serious adverse events (SAEs), occurrence of AEs of specific interest
Starting date	March 2013
Contact information	Please refer to this study by its ClinicalTrials.gov identifier: NCT01751165
Notes	This study is ongoing, but not recruiting participants. No publications provided Secondary ID: EudraCT number 2012‐004456‐11 or Study ID: 116697